Perospirone, a novel atypical antipsychotic drug, potentiates fluoxetine-induced increases in dopamine levels via multireceptor actions in the rat medial prefrontal cortex
- 24 June 2004
- journal article
- research article
- Published by Elsevier BV in Neuroscience Letters
- Vol. 364 (1), 16-21
- https://doi.org/10.1016/j.neulet.2004.03.079
Abstract
No abstract availableKeywords
This publication has 23 references indexed in Scilit:
- Amantadine as augmentation therapy in the management of treatment-resistant depressionInternational Clinical Psychopharmacology, 2003
- Fluoxetine Increases Extracellular Dopamine in the Prefrontal Cortex by a Mechanism Not Dependent on SerotoninJournal of Neurochemistry, 2001
- Changes in Regional Brain Glucose Metabolism Measured With Positron Emission Tomography After Paroxetine Treatment of Major DepressionAmerican Journal of Psychiatry, 2001
- A Novel Augmentation Strategy for Treating Resistant Major DepressionAmerican Journal of Psychiatry, 2001
- Synergistic Effects of Olanzapine and Other Antipsychotic Agents in Combination with Fluoxetine on Norepinephrine and Dopamine Release in Rat Prefrontal CortexNeuropsychopharmacology, 2000
- In VivoEvidence for the Involvement of Dopamine-D2Receptors in Striatum and Anterior Cingulate Gyrus in Major DepressionNeuroImage, 1997
- Buspirone Enhances Duloxetine‐ and Fluoxetine‐Induced Increases in Dialysate Levels of Dopamine and Noradrenaline, but Not Serotonin, in the Frontal Cortex of Freely Moving RatsJournal of Neurochemistry, 1997
- Blockade of the Noradrenaline Carrier Increases Extracellular Dopamine Concentrations in the Prefrontal Cortex: Evidence that Dopamine Is Taken up In Vivo by Noradrenergic TerminalsJournal of Neurochemistry, 1990
- Binding Profile of SM-9018, a Novel Antipsychotic CandidateThe Japanese Journal of Pharmacology, 1990
- Pharmacological Actions of SM-9018, a New Neuroleptic Drug with Both Potent 5-Hydroxytryptamine2 and Dopamine2 Antagonistic ActionsThe Japanese Journal of Pharmacology, 1990